SHR-1702
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
August 24, 2023
A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
(clinicaltrials.gov)
- P1 | N=31 | Completed | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Active, not recruiting ➔ Completed | Trial completion date: Jun 2022 ➔ Feb 2023 | Trial primary completion date: Jun 2022 ➔ Feb 2023
Monotherapy • Trial completion • Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology
June 05, 2023
A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors
(clinicaltrials.gov)
- P1 | N=8 | Terminated | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | N=84 ➔ 8 | Unknown status ➔ Terminated; Sponsor R & D Strategy Adjustment
Enrollment change • Metastases • Trial termination • Oncology • Solid Tumor
March 09, 2022
A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
(clinicaltrials.gov)
- P1 | N=31 | Active, not recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Recruiting ➔ Active, not recruiting | Trial primary completion date: Dec 2021 ➔ Jun 2022
Enrollment closed • Monotherapy • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology
March 17, 2021
A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
(clinicaltrials.gov)
- P1; N=42; Recruiting; Sponsor: Jiangsu HengRui Medicine Co., Ltd.; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Monotherapy • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology
June 23, 2020
A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
(clinicaltrials.gov)
- P1; N=36; Not yet recruiting; Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Clinical • Monotherapy • New P1 trial • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology
1 to 5
Of
5
Go to page
1